A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...

Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

UK group Cycle Pharma has made an unsolicited ... The potential sales revenue growth from those products is likely part of the interest in Vanda, along with the prospects for pipeline drugs.

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...

Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the ...